NCI Cancer Bulletin: Top 10 Feature Stories Since January

August 24, 2010 Dear NCI Cancer Bulletin Subscriber, The editors, writers, and technical staff of the NCI Cancer Bulletin would like to thank each of you for your continued interest in our newsletter. We will not publish an issue today due to our summer production break, but we will resume biweekly publication on September 7. In the meantime, we have compiled a list below of the 10 most popular feature-length stories published so far this year, according to reader page views: FDA Approves First Therapeutic Cancer Vaccine (May 4) Physicians Urged to Consider Active Surveillance in Prostate Cancer (Jan. 12) Experimental Drug Benefits Patients with Advanced Prostate Cancer (Mar. 9) Chemotherapy-induced Peripheral Neuropathy (Feb. 23) The Downside of Diagnostic Imaging (Jan. 26) Melanoma Drugs Have Unintended Effects in Some Tumors (Feb. 9) New Cancer Drugs Bring New Side Effects, and Nurses Respond (Jan. 12) Trials Point to Potential Advances in Lung Cancer Treatment (Jan. 26) Personalizing Biomarkers for Cancer (Feb. 23) I-SPY2: Breast Cancer Trial Aims to Speed Drugs to the Clinic (Mar. 23) We are especially proud of our ability to bring you stories like these through RSS and Twitter feeds, as well as to present our content via a variety of platforms like YouTube and Facebook. In addition, for those who may prefer to read selected articles in Spanish, we have a Spanish-language version of the newsletter. Thank you again for your interest and support. We hope you’ll continue to read each issue and encourage others to subscribe. Best regards, The NCI Cancer Bulletin Team